Most of the studies that evaluate the performance of AI-based medical solutions are retrospectively done based on the existing diagnosis data.
This prospective study is valuable as it can validate the overall performance of DeepDx-Prostate in a real-world setting.
Beatrice Knudsen, Medical Director of Digital and Computational Pathology at ARUP Laboratories and the principal investigator of the study said,
“We have high expectations for the impact of DeepDx-Prostate in the clinical practice environment and anticipate the study to draw data on how pathologists can use AI-based solutions to enhance efficiency and accuracy of diagnosis.”
Deep also interested to make collaborations in various cancer diagnosis, prognosis, and prediction studies with ARUP Laboratories since the university accepted the joint research deal in May.
A person with more than 5 years of experience in the field of news, a very talented writer